Individuelle Dosimetrie bei der Radiojodtherapie

K. Kulkarni, D. Van Nostrand, F. Atkins, M. Aiken, K. Burman, L. Wartofsky, The Relative Frequency in Which Empiric Dosages of Radioiodine Would Potentially Overtreat or Undertreat Patients Who Have Metastatic Well-Differentiated Thyroid Cancer Thyroid. ,vol. 16, pp. 1019- 1023 ,(2006) , 10.1089/THY.2006.16.1019

Glenn D. Flux, Masud Haq, Sarah J. Chittenden, Susan Buckley, Cecilia Hindorf, Kate Newbold, Clive L. Harmer, A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 37, pp. 270- 275 ,(2010) , 10.1007/S00259-009-1261-3

M. Dietlein, M. Biermann, M. Frühwald, T. Linden, P. Bucsky, C. Reiners, O. Schober, C. Franzius, [Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer]. Nuklearmedizin-nuclear Medicine. ,vol. 46, pp. 224- 231 ,(2007) , 10.1160/NUKMED-0288

Frederik A. Verburg, Michael Lassmann, Uwe Mäder, Markus Luster, Christoph Reiners, Heribert Hänscheid, The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 38, pp. 673- 680 ,(2011) , 10.1007/S00259-010-1689-5

Frederik A. Verburg, Heribert Hänscheid, Johannes Biko, Maria C. Hategan, Michael Lassmann, Michael C. Kreissl, Christoph Reiners, Markus Luster, Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 37, pp. 896- 903 ,(2010) , 10.1007/S00259-009-1303-X

Katherine S. Kolbert, George Sgouros, George Sgouros, Keith S. Pentlow, Richard J. Robbins, Steven M. Larson, Edward F. Mun, Arif Sheikh, Axel Barth, Patient-Specific Dosimetry for 131I Thyroid Cancer Therapy Using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) Software The Journal of Nuclear Medicine. ,vol. 45, pp. 1366- 1372 ,(2004)

F. Pacini, P. W. Ladenson, M. Schlumberger, A. Driedger, M. Luster, R. T. Kloos, S. Sherman, B. Haugen, C. Corone, E. Molinaro, R. Elisei, C. Ceccarelli, A. Pinchera, R. L. Wahl, S. Leboulleux, M. Ricard, J. Yoo, N. L. Busaidy, E. Delpassand, H. Hanscheid, R. Felbinger, M. Lassmann, C. Reiners, Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. The Journal of Clinical Endocrinology and Metabolism. ,vol. 91, pp. 926- 932 ,(2006) , 10.1210/JC.2005-1651

Joanna Klubo-Gwiezdzinska, Douglas Van Nostrand, Frank Atkins, Kenneth Burman, Jacqueline Jonklaas, Mihriye Mete, Leonard Wartofsky, Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. ,vol. 96, pp. 3217- 3225 ,(2011) , 10.1210/JC.2011-0494

David S. Cooper, Gerard M. Doherty, Bryan R. Haugen, Richard T. Kloos, Stephanie L. Lee, Susan J. Mandel, Ernest L. Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger, Steven I. Sherman, David L. Steward, R. Michael Tuttle, Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer Thyroid. ,vol. 19, pp. 1167- 1214 ,(2009) , 10.1089/THY.2009.0110

Frederik A. Verburg, Johannes Biko, Stefanie Diessl, Yuri Demidchik, Valentina Drozd, Scott A. Rivkees, Christoph Reiners, Heribert Hänscheid, I-131 Activities as High as Safely Administrable (AHASA) for the Treatment of Children and Adolescents with Advanced Differentiated Thyroid Cancer The Journal of Clinical Endocrinology and Metabolism. ,vol. 96, ,(2011) , 10.1210/JC.2011-0520